The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by PAR-18-530.
Who won it before
43 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $23,992,009 in first-year total cost, median $589,726.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-Q (57)]29
- Special Emphasis Panel[ZRG1 SBIB-D (57)]14
Most frequent institutions
- CASE WESTERN RESERVE UNIVERSITY4
- EMORY UNIVERSITY3
- MASSACHUSETTS GENERAL HOSPITAL2
- STANFORD UNIVERSITY2
- UNIVERSITY OF CALIFORNIA AT DAVIS2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer Characterization1R01CA218187-01A1 | CATANA, CIPRIAN | MASSACHUSETTS GENERAL HOSPITAL, MA | $684,119 | ZRG1 |
| 2018 | Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal Carcinoma1R01CA220581-01A1 | LEWIS, JAMESMADABHUSHI, ANANT | CASE WESTERN RESERVE UNIVERSITY, OH | $671,111 | ZRG1 |
| 2018 | Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers1R01CA216579-01A1 | MADABHUSHI, ANANTVELCHETI, VAMSIDHAR | CASE WESTERN RESERVE UNIVERSITY, OH | $670,734 | ZRG1 |
| 2018 | Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy1R01CA218195-01A1 | CREMER, MIRIAM | CLEVELAND CLINIC LERNER COM-CWRU, OH | $669,209 | ZRG1 |
| 2018 | An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.1R01CA214428-01A1 | KEMP, CHRISTOPHER J | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $647,099 | ZRG1 |
| 2018 | Translating buccal nanocytology for lung cancer screening into clinical practice1R01CA225002-01A1 | BACKMAN, VADIMROY, HEMANT K.SUBRAMANIAN, HARIHARAN | NORTHWESTERN UNIVERSITY, IL | $638,469 | ZRG1 |
| 2018 | Molecular Digital CytoImaging for Leukemia Drug Screening1R01CA222095-01A1 | MARTIN, JODYVU, TOTHU Q | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $605,517 | ZRG1 |
| 2018 | Clinical platform for high-throughput analyses of extracellular vesicles1R01CA229777-01 | LEE, HAKHOSKOG, JOHAN | MASSACHUSETTS GENERAL HOSPITAL, MA | $597,308 | ZRG1 |
| 2018 | Sharpening the edge in pencil-beam proton therapy: an aftermarket collimation system to better spare normal tissue during radiation treatment1R37CA226518-01A1 | HYER, DANIEL ELLIS | UNIVERSITY OF IOWA, IA | $589,726 | ZRG1 |
| 2018 | Academic-Industry Partnership for the Translation of a Novel Optical Imaging Approach to guide Endocrine Cancer Surgery1R01CA212147-01A1 | MAHADEVAN-JANSEN, ANITA | VANDERBILT UNIVERSITY, TN | $563,912 | ZRG1 |
| 2018 | Next generation small animal radiation research platform1R37CA214639-01A1 | JIA, XUN | UT SOUTHWESTERN MEDICAL CENTER, TX | $545,755 | ZRG1 |
| 2018 | Clinical Translation of Stimulated Raman Histology1R01CA226527-01 | ORRINGER, DANIEL | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $529,945 | ZRG1 |
| 2018 | Radioluminescence dosimetry solution for precision radiation therapy1R01CA223667-01A1 | XING, LEI | STANFORD UNIVERSITY, CA | $521,555 | ZRG1 |
| 2018 | Molecular complete response in blood as a predictor for pathologic complete response after neoadjuvant therapy for breast cancer1R01CA214494-01A1 | PARK, BEN HO | JOHNS HOPKINS UNIVERSITY, MD | $224,662 | ZRG1 |
| 2017 | CLINICAL TRANSLATION OF HYPERPOLARIZED 13C-UREA FOR CANCER MR MOLECULAR IMAGING1R01CA214554-01 | FERRONE, MARCUSHURD, RALPH EUGENEKURHANEWICZ, JOHN | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $684,591 | ZRG1 |
| 2017 | Large aperture and wideband modular ultrasound arrays for the diagnosis of liver cancer1R01CA211602-01A1 | FERRARA, KATHERINE WTRAHEY, GREGG E.ZHOU, QIFA | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $667,368 | ZRG1 |
| 2017 | A Novel Molecular Imaging Agent for Surgical Resection of Invasive Brain Tumors1R01CA217956-01 | BRADY-KALNAY, SUSANN MGASTINEAU, EDWARDSLOAN, ANDREW E | CASE WESTERN RESERVE UNIVERSITY, OH | $662,909 | ZRG1 |
| 2017 | Focal Laser Ablation of Prostate Cancer using MR/US Fusion1R01CA218547-01 | HU, JIMMARKS, LEONARD STEPHENNATARAJAN, SHYAMSONN, GEOFFREY | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $627,518 | ZRG1 |
| 2017 | A blood test to identify prostate cancer patients at risk for visceral metastasis1R01CA218356-01 | POSADAS, EDWIN MELENCIOTSENG, HSIAN-RONG | CEDARS-SINAI MEDICAL CENTER, CA | $620,500 | ZRG1 |
| 2017 | Translation of a Clinical Molecular Diagnostic Assay for Bladder Cancer1R01CA206584-01A1 | GOODISON, STEVE | MAYO CLINIC JACKSONVILLE, FL | $618,256 | ZRG1 |
| 2017 | Development of a Four-Class, Molecular Subtyping Diagnostic for HPV-negative Head and Neck Cancer1R01CA211939-01A1 | HAYES, DAVID NZEVALLOS, JOSE P. | WASHINGTON UNIVERSITY, MO | $615,138 | ZRG1 |
| 2017 | A novel point of care test for oral and oropharyngeal cancer risk1R01CA204264-01A1 | CALIFANO, JOSEPH AFRANZMANN, ELIZABETH J | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $593,922 | ZRG1 |
| 2017 | Image guided targeted biopsy of clinically significant prostate cancer with acoustic radiation force2R01CA142824-06A1 | NIGHTINGALE, KATHRYN RADABAUGH | DUKE UNIVERSITY, NC | $546,174 | ZRG1 |
| 2017 | Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells2R01CA134633-05 | AHRENS, ERIC T.COHEN, EZRA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $540,493 | ZRG1 |
| 2017 | Targeted Molecular Imaging of Plectin-1; Bench to bedside and back again1R01CA216879-01 | KELLY, KIMBERLY A.SUTCLIFFE, JULIE L | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $524,668 | ZRG1 |
| 2017 | Automated Volumetric Molecular Ultrasound for Breast Cancer Imaging1R01CA218204-01 | DAHL, JEREMYDANIEL, BRUCE LDEMARTINI, WENDY | STANFORD UNIVERSITY, CA | $477,755 | ZRG1 |
| 2017 | 2D MR Correlational Spectroscopy Platform for Molecular and Genetic Characterizations of Glioma1R01CA203388-01A1 | MAO, HUIZHONG, XIAODONG | EMORY UNIVERSITY, GA | $427,689 | ZRG1 |
| 2017 | Markerless Motion Tracking of Lung Tumors Using Dual Energy Imaging1R01CA207483-01A1 | MOSTAFAVI, HASSANROESKE, JOHN | LOYOLA UNIVERSITY CHICAGO, IL | $385,045 | ZRG1 |
| 2017 | Improving the in vivo delivery and antitumor efficacy of antisense drugs1R01CA214550-01 | PANG, HONGBO | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $110,639 | ZRG1 |
| 2016 | Transforming the diagnosis and care of patients with CTCL using TCR sequencing1R01CA203721-01 | CLARK, RACHAEL ANNKUPPER, THOMAS S. | BRIGHAM AND WOMEN'S HOSPITAL, MA | $742,632 | ZRG1 |
| 2016 | Computerized histologic image predictor of cancer outcome1R01CA202752-01A1 | FELDMAN, MICHAEL DGANESAN, SHRIDARMADABHUSHI, ANANT | CASE WESTERN RESERVE UNIVERSITY, OH | $699,670 | ZRG1 |
| 2016 | Development of novel selective Rac inhibitors for refractory leukemias1R01CA202756-01A1 | WILLIAMS, DAVID A | BOSTON CHILDREN'S HOSPITAL, MA | $638,223 | ZRG1 |
| 2016 | Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung SABR1R01CA202761-01A1 | SAWANT, AMITTIMMERMAN, ROBERT D | UNIVERSITY OF MARYLAND BALTIMORE, MD | $608,909 | ZRG1 |
| 2016 | Integrated Tools for Quantitative Whole-Body Tumor Perfusion Imaging1R01CA202695-01A1 | GREEN, MARK AHUTCHINS, GARY D | INDIANA UNIVERSITY INDIANAPOLIS, IN | $591,408 | ZRG1 |
| 2016 | Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer1R01CA202762-01A1 | RICIGLIANO, MARKYU, KENNETH H. | SLOAN-KETTERING INST CAN RESEARCH, NY | $575,993 | ZRG1 |
| 2016 | Biomarkers of Molecular Age to Predict the Toxicity of Cancer Chemotherapy1R01CA203023-01 | ELAM, AMANDAMITIN, NATALIAMUSS, HYMANSHARPLESS, NORMAN E | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $572,222 | ZRG1 |
| 2016 | Integrated Discovery Pipeline for Tumor Neoantigens1R01CA204261-01A1 | CARRENO, BEATRIZ M.LINETTE, GERALD P | UNIVERSITY OF PENNSYLVANIA, PA | $562,825 | ZRG1 |
| 2016 | Real-time monitoring of circulating pancreatic tumor cells and clusters1R01CA207643-01 | CARPENTER, ERICA | UNIVERSITY OF PENNSYLVANIA, PA | $544,582 | ZRG1 |
| 2016 | Membrane-based immunotherapy for triple negative breast cancer- a partnered approach1R01CA202763-01A1 | PACK, CHRISTOPHER DSELVARAJ, PERIASAMY | EMORY UNIVERSITY, GA | $502,655 | ZRG1 |
| 2016 | A partnership to enable clinical ctDNA testing for breast cancer recurrence1R01CA204253-01 | VARLEY, KATHERINE ELENA | UNIVERSITY OF UTAH, UT | $481,993 | ZRG1 |
| 2016 | Development of cell-free DNA assays for HCC screening and liquid biopsy1R01CA202769-01 | SU, YING-HSIU | BARUCH S. BLUMBERG INSTITUTE, PA | $432,900 | ZRG1 |
| 2016 | Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles1R01CA202846-01 | MAO, HUIWANG, YONGQIANG ANDREWYANG, LILY | EMORY UNIVERSITY, GA | $425,268 | ZRG1 |
| 2016 | Development of Anatomical Patient Models to Facilitate MR-only Treatment Planning1R01CA204189-01A1 | GLIDE-HURST, CARRI KAYE | HENRY FORD HEALTH SYSTEM, MI | $350,943 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.